Estimated SR&ED Credits
Canada’s biotechnology and life sciences sector is a global leader in genomics, personalized medicine, and novel drug delivery systems. In 2026, the intersection of bioinformatics and lab-based research is where the most significant breakthroughs occur. Companies are dedicated to solving complex biological problems, from developing targeted cancer therapies to creating sustainable agricultural bio-products. This work is inherently risky and requires a long-term commitment to scientific discovery, particularly in the development of mRNA-based therapies and synthetic biology applications.
SR&ED eligibility in biotechnology is deeply rooted in the scientific method. Whether you are conducting stability testing on a new formulation or developing high-throughput screening protocols, the inherent uncertainties of biological systems make this work highly eligible. However, the documentation requirements are stringent. Eligibility often hinges on the systematic investigation of protein folding or the optimization of bioreactor yields where results are unpredictable. These projects must move beyond standard laboratory protocols to demonstrate a true technological advancement in the medical or biological sciences.
GrowWise offers value by bridging the gap between the laboratory and the tax office. We ensure your technical narratives satisfy the rigorous scientific uncertainty requirements of a CRA audit while you focus on life-saving research. Our consultants help you track every eligible expense, from lab supplies to specialized subcontractor fees. By leveraging GrowWise expertise, biotech firms can secure the funding necessary to move through the expensive stages of clinical trials and product development with confidence.
